Experimentally-driven mathematical modeling to improve combination targeted and cytotoxic therapy for HER2+ breast cancer.

ABSTRACT: The goal of this study is to experimentally and computationally investigate combination trastuzumab-paclitaxel therapies and identify potential synergistic effects due to sequencing of the therapies with in vitro imaging and mathematical modeling. Longitudinal alterations in cell confluence are reported for an in vitro model of BT474 HER2+ breast cancer cells following various dosages and timings of paclitaxel and trastuzumab combination regimens. Results of combination drug regimens are evaluated for drug interaction relationships based on order, timing, and quantity of dose of the drugs. Altering the order of treatments, with the same total therapeutic dose, provided significant changes in overall cell confluence (p < 0.001). Two mathematical models are introduced that are constrained by

SUBMITTER: Jarrett AM 

PROVIDER: S-EPMC6731321 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature